These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12451199)

  • 1. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment.
    Clifford DB; McArthur JC; Schifitto G; Kieburtz K; McDermott MP; Letendre S; Cohen BA; Marder K; Ellis RJ; Marra CM;
    Neurology; 2002 Nov; 59(10):1568-73. PubMed ID: 12451199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex.
    Bjugstad KB; Flitter WD; Garland WA; Philpot RM; Kirstein CL; Arendash GW
    J Neurovirol; 2000 Dec; 6(6):478-91. PubMed ID: 11175320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment.
    Schifitto G; Zhang J; Evans SR; Sacktor N; Simpson D; Millar LL; Hung VL; Miller EN; Smith E; Ellis RJ; Valcour V; Singer E; Marra CM; Kolson D; Weihe J; Remmel R; Katzenstein D; Clifford DB;
    Neurology; 2007 Sep; 69(13):1314-21. PubMed ID: 17652642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.
    Neurology; 1997 Jul; 49(1):142-6. PubMed ID: 9222182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.
    Heseltine PN; Goodkin K; Atkinson JH; Vitiello B; Rochon J; Heaton RK; Eaton EM; Wilkie FL; Sobel E; Brown SJ; Feaster D; Schneider L; Goldschmidts WL; Stover ES
    Arch Neurol; 1998 Jan; 55(1):41-51. PubMed ID: 9443710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CPI-1189. Centaur.
    Müller T
    Curr Opin Investig Drugs; 2002 Dec; 3(12):1763-7. PubMed ID: 12528314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment.
    Nakasujja N; Miyahara S; Evans S; Lee A; Musisi S; Katabira E; Robertson K; Ronald A; Clifford DB; Sacktor N
    Neurology; 2013 Jan; 80(2):196-202. PubMed ID: 23269596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.
    Schifitto G; Navia BA; Yiannoutsos CT; Marra CM; Chang L; Ernst T; Jarvik JG; Miller EN; Singer EJ; Ellis RJ; Kolson DL; Simpson D; Nath A; Berger J; Shriver SL; Millar LL; Colquhoun D; Lenkinski R; Gonzalez RG; Lipton SA; ; ;
    AIDS; 2007 Sep; 21(14):1877-86. PubMed ID: 17721095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial.
    Sacktor N; Skolasky RL; Moxley R; Wang S; Mielke MM; Munro C; Steiner J; Nath A; Haughey N; McArthur J
    J Neurovirol; 2018 Feb; 24(1):16-27. PubMed ID: 29063516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor function and human immunodeficiency virus-associated cognitive impairment in a highly active antiretroviral therapy-era cohort.
    Robinson-Papp J; Byrd D; Mindt MR; Oden NL; Simpson DM; Morgello S;
    Arch Neurol; 2008 Aug; 65(8):1096-101. PubMed ID: 18695060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia.
    Sevigny JJ; Albert SM; McDermott MP; McArthur JC; Sacktor N; Conant K; Schifitto G; Selnes OA; Stern Y; McClernon DR; Palumbo D; Kieburtz K; Riggs G; Cohen B; Epstein LG; Marder K
    Neurology; 2004 Dec; 63(11):2084-90. PubMed ID: 15596754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selegiline and oxidative stress in HIV-associated cognitive impairment.
    Schifitto G; Yiannoutsos CT; Ernst T; Navia BA; Nath A; Sacktor N; Anderson C; Marra CM; Clifford DB;
    Neurology; 2009 Dec; 73(23):1975-81. PubMed ID: 19890073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium.
    Schifitto G; Sacktor N; Marder K; McDermott MP; McArthur JC; Kieburtz K; Small S; Epstein LG
    Neurology; 1999 Jul; 53(2):391-6. PubMed ID: 10430432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial.
    Sacktor N; Miyahara S; Deng L; Evans S; Schifitto G; Cohen BA; Paul R; Robertson K; Jarocki B; Scarsi K; Coombs RW; Zink MC; Nath A; Smith E; Ellis RJ; Singer E; Weihe J; McCarthy S; Hosey L; Clifford DB;
    Neurology; 2011 Sep; 77(12):1135-42. PubMed ID: 21900636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychological characterization of the AIDS dementia complex and rationalization of a test battery.
    Maruff P; Currie J; Malone V; McArthur-Jackson C; Mulhall B; Benson E
    Arch Neurol; 1994 Jul; 51(7):689-95. PubMed ID: 8018042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neuropsychological evaluation of the cognitive deficits in infection by human immunodeficiency virus type 1 (HIV-1)].
    Clemente-Millana L; Portellano JA
    Rev Neurol; 2000 Dec 16-31; 31(12):1192-201. PubMed ID: 11205557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation.
    Pulliam L; Irwin I; Kusdra L; Rempel H; Flitter WD; Garland WA
    Brain Res; 2001 Mar; 893(1-2):95-103. PubMed ID: 11222997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study.
    Simioni S; Cavassini M; Annoni JM; Métral M; Iglesias K; Rimbault Abraham A; Jilek S; Calmy A; Müller H; Fayet-Mello A; Giacobini E; Hirschel B; Du Pasquier RA
    Neurology; 2013 Feb; 80(6):553-60. PubMed ID: 23345635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HIV Dementia Scale: predictive power in mild dementia and HAART.
    Bottiggi KA; Chang JJ; Schmitt FA; Avison MJ; Mootoor Y; Nath A; Berger JR
    J Neurol Sci; 2007 Sep; 260(1-2):11-5. PubMed ID: 17482212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.